🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11873296

Solid forms of a dual RAF/MEK inhibitor

VERASTEM, INC. · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11872261

Lipoprotein targeting protease inhibitors and uses

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866418

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement

BioCryst Pharmaceuticals, Inc. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11865125

APKC inhibitors and methods of treating a neurodegenerative disease or disorder

United States Government as represented by the Department of Veterans Affairs · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866446

Inhibitors of APOL1 and methods of using same

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11865134

Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858925

GAS41 inhibitors and methods of use thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858937

Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibito

Lead Discovery Center GmbH · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858915

Polo like kinase 4 inhibitors

ORIC PHARMACEUTICALS, INC. · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858957

Ectonucleotidase inhibitors and methods of use thereof

ANTENGENE THERAPEUTICS LIMITED · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858927

Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing

HEPAREGENIX GMBH · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858930

Fused bicyclic RAF inhibitors and methods for use thereof

Jazz Pharmaceuticals Ireland Limited · Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851449

Heterocyclic amide compounds having an RORvt inhibitory action

Takeda Pharmaceutical Company Limited · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851443

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844779

PKC-Delta-I inhibitor formulations and uses thereof

United States Government as represented by the Department of Veterans Affairs · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844801

Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

Aclaris Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845989

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844799

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting r

Actinium Phamaceuticals, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845747

Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845808

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840540

Dimers of covalent NFKB inhibitors

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840536

Heterocyclic inhibitors of PTPN11

The Board of Regents of the University of Texas System · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840525

Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer

NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833160

Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseas

UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted